Answers are grounded in this paper and cite their sources.
Bispecific antibodies (BsAbs) and chimeric antigen receptor T-cell (CAR-T) therapies have transformed the treatment of hematologic malignancies, but infectious complications remain a leading cause of morbidity and mortality. We conducted a multicenter international survey across 101 institutions—predominantly academic tertiary hospitals (80.2%)—to characterize contemporary prevention and management practices. We assessed antimicrobial prophylaxis, infection surveillance, and management of therapy-induced immunodeficiency for patients receiving BsAbs and/or CAR-T. Practices were highly heterogeneous. According to respondents’ perception, viral infections were the most frequent with BsAbs (69.3%), whereas bacterial infections predominated after CAR-T (52.8%). Anti–Pneumocystis jirovecii prophylaxis was nearly universal (93.5% BsAbs; 97.5% CAR-T), but antibacterial and antifungal prophylaxis varied widely and were omitted in 86% and 38.7% of BsAb centers, respectively. CMV monitoring strategies differed markedly; one-third of BsAb centers did not routinely monitor CMV-DNA. Most respondents identified better guidelines (72.3% BsAbs; 52.8% CAR-T), improved diagnostic tools, and multidisciplinary approaches as priorities. These findings underscore substantial practice variation and the urgent need for harmonized, evidence-based guidance, particularly in light of recent data highlighting prolonged hypogammaglobulinemia, infection burden per patient-month with continuously dosed BsAbs, and the potential protective effect of immunoglobulin replacement. Prospective studies are warranted to define optimal prophylaxis, surveillance, and immunoglobulin replacement strategies in these populations.
No takes yet. Share an insight, caveat, or question.
Infante et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: